Manila Times Business
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the "Company” or "Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases ("NIAID”), part of the National Institutes of Health ("NIH”), in connection with the Company’s contract supporting development of the VXV-01 f
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Hypercharge Announces Issuance of Option Grants
6h ago
Mark Leeds, D.O. PA Launches FloridaTaper.com, a Free Educational Resource on Benzodiazepine Tapering, Withdrawal, and BIND
6h ago
Zentro Announces Expansion of Digital Asset Services Focused on Liquidity and Payment Solutions in the United Arab Emirates
6h ago
DNA My Dog Expands Product Suite With Launch of New Health and Trait Test, Building on 18-Year Foundation in Canine Genetic Testing
6h ago